◀ Back to CDKN1A

BCR — CDKN1A

Text-mined interactions from Literome

Keeshan et al., Leukemia 2001 : Despite the drug-resistant phenotype, high Bcr-Abl levels concomitantly increased the expression of p53, p21 , Bax and down-regulated Bcl-2
Pierce et al., Hematol J 2001 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : This enhanced BCR/ABL mediated growth inhibition occurred over a range of growth factor concentrations and was independent of changes in p21 ( Cip1 ) and p27 ( Kip ) levels
Keeshan et al., Br J Haematol 2003 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K) independent pathway
Rangatia et al., Leukemia 2006 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : Lack of BCR-ABL leads to cell cycle arrest in G1 phase as observed by decrease in cyclin D1 and increase in p21 and p27 cdk inhibitors mRNA